Patent ID: 8444984

Claim:
A method of treating a subject for a TNFα-related condition, comprising: administering monoclonal antibody to a mammalian subject having a TNFα-related condition in an amount effective to treat said subject for at least one symptom of said TNF-α-related condition, wherein said monoclonal antibody neutralizes TNFα activity and comprises: a) a variable domain comprising: i. a heavy chain variable region comprising a CDR1 region identical to amino acid residues 30-34 of SEQ ID NO: 31, a CDR2 region identical to amino acid residues 49-64 of SEQ ID NO: 31 and a CDR3 region identical to amino acid residues 97-109 of SEQ ID NO: 31; and ii. a light chain variable region comprising a CDR1 region identical to amino acid residues 23-33 of SEQ ID NO: 75, a CDR2 region identical to amino acid residues 49-55 of SEQ ID NO: 75 and a CDR3 region identical to amino acid residues 88-99 of SEQ ID NO: 75; or b) a variant of said variable domain of part a) that is otherwise identical to said variable domain of part a) except for up to 10 amino acid substitutions in said CDR regions.